Last updated: 11/03/2018 09:03:46

Efficacy of RTS,S/AS01 vaccine against episodes of malaria due to P. falciparum infection in children.

Request patient level data
GSK study ID
106464
See study documents
Clinicaltrials.gov ID
NCT00380393
See results summary
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A study of the efficacy against episodes of clinical malaria due to P. falciparum infection of GSK Biologicals candidate vaccine RTS,S/AS01, administered according to a 0,1,2-months schedule in children aged 5 to 17 months living in Tanzania & Kenya
Trial description: This phase IIb trial is being done to find out if the RTS,S/AS01 vaccine helps to prevent children from falling ill with malaria and to evaluate vaccine safety.
The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
Double (Care Provider, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Frequency of first case of malaria meeting the primary case definition

Timeframe: Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Secondary outcomes:

Frequency of first case malaria meeting the secondary case definition

Timeframe: Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Multiple events of malaria meeting the primary case definition

Timeframe: Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Multiple events of malaria meeting the secondary case definition

Timeframe: Assessed over average of 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Number of subjects positive for P. falciparum parasitaemia

Timeframe: At the Cross-Sectional Visit that took place for each participant at on average 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Geometric mean density of asexual P. falciparum parasite

Timeframe: At the Cross-Sectional Visit that took place for each participant at on average 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Haemoglobin values at Cross-Sectional Visit

Timeframe: At the Cross-Sectional Visit that took place for each participant at on average 7.8 months post Dose 3 (range 4.3 to 10.3 months)

Number of subjects with any and Grade 3 solicited local symptoms

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Number of subjects with any, Grade 3 and related solicited general symptoms

Timeframe: During the 7-day (Days 0-6) post-vaccination period following each dose and across doses

Number of subjects with any unsolicited adverse events (AEs)

Timeframe: Within the 30-day (Days 0-29) post-vaccination follow-up period

Number of subjects with serious adverse events (SAEs)

Timeframe: Throughout the study period (Day 0 - Month 14)

Number of subjects with hemoglobin values outside normal ranges with toxicity grades

Timeframe: At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)

Number of subjects with white blood cell (WBC) values outside normal ranges with toxicity grades

Timeframe: At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)

Number of subjects with platelet values outside normal ranges with toxicity grades

Timeframe: At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)

Number of subjects with Alanine aminotransferase (ALT) values outside normal ranges with toxicity grades

Timeframe: At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)

Number of subjects with Creatinine values outside normal ranges with toxicity grades

Timeframe: At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)

Concentration of antibodies against the P. falciparum circumsporozoite (CS) repeat domain (anti-CS)

Timeframe: At Day 0, Month 3 and at Cross-sectional Visit (took place between 7 and 13 months post Dose 1, mean: 10 months, standard deviation: 1.29)

Concentration of antibodies against hepatitis B surface antigen (anti-HBs)

Timeframe: At Day 0 and at Month 3

Frequency of cluster of differentiation 4 (CD4+) CS-specific T-cells

Timeframe: Prior to vaccination (Day 0)

Frequency of cluster of differentiation 8 (CD8+) CS-specific T-cells

Timeframe: Prior to vaccination (Day 0)

Frequency of cluster of differentiation 4 (CD4+) CS-specific T-cells

Timeframe: At Month 3

Frequency of cluster of differentiation 8 (CD8+) CS-specific T-cells

Timeframe: At Month 3

Interventions:
Biological/vaccine: GSK malaria vaccine 257049 Vaccine
Biological/vaccine: Sanofi-Pasteur’s Human Diploid Cell Rabies Vaccine
Enrollment:
894
Observational study model:
Not applicable
Primary completion date:
2008-15-08
Time perspective:
Not applicable
Clinical publications:
Bejon P et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med. 359(24): 2521-2532.
Lang TA et al. (2012) Approaching the community about screening children for a multicentre malaria vaccine trial. International Health Journal. 4(1):47-54.
Lusingu J et al. (2010) Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian children. PLoS One. 5(11):e14090.
Olotu A et al. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 11(2):102-109. Epub
Bejon P et al. (2011) Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J Infect Dis. 204(1):9-18.
Bejon P et al. (2011) Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites. PLoS One. 6(6):e21711.
Miura K et al. (2014) Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes. Malar J. 13:263.
Olotu A et al. (2011) Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. PLoS One. 6(10):e25786.
Olotu A et al. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis. 11(2):102-109.
Olotu A et al. (2014) Avidity of Anti-Circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children. PLoS One. 9(12):e115126.
Olotu A et al. (2016) Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med. 374(26):2519-2529.
Medical condition
Malaria
Product
SB257049
Collaborators
Not applicable
Study date(s)
January 2007 to November 2008
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
5 - 17 months
Accepts healthy volunteers
Yes
  • A male or female child of between 5 months and 17 months of age at the time of first vaccination.
  • Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child..
  • Acute disease at the time of enrolment.
  • Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.
Inclusion and exclusion criteria
Inclusion criteria:
  • A male or female child of between 5 months and 17 months of age at the time of first vaccination.
  • Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child..
  • Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
Exclusion criteria:
  • Acute disease at the time of enrolment.
  • Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.
  • Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of acceptable limits.
  • Planned administration/administration of a vaccine not foreseen by the study within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid or scheduled diphtheria, pertussis or measles vaccine.
  • Use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose
  • Previous participation in any other malaria vaccine trial.
  • Simultaneous participation in any other clinical trial.
  • Same sex twin.
  • History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Amani, Tanga, Tanzania
Status
Study Complete
Contact us
Location
GSK Investigational Site
Kilifi, Kenya, 80108
Status
Study Complete
Contact us

Study documents

Clinical study report
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2008-15-08
Actual study completion date
2008-11-11

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website